0000899243-18-030265.txt : 20181206
0000899243-18-030265.hdr.sgml : 20181206
20181206170501
ACCESSION NUMBER: 0000899243-18-030265
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181204
FILED AS OF DATE: 20181206
DATE AS OF CHANGE: 20181206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rolfe Lindsey
CENTRAL INDEX KEY: 0001650504
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 181221402
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-04
0
0001466301
Clovis Oncology, Inc.
CLVS
0001650504
Rolfe Lindsey
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2018-12-04
4
M
0
625
A
14446
D
Common Stock
2018-12-04
4
S
0
284
21.23
D
14162
D
Restricted Stock Units
2018-12-04
4
M
0
625
0.00
D
Common Stock
625
5625
D
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance
/s/ Lindsey Rolfe
2018-12-05